OS Fund
| Company type | Private |
|---|---|
| Industry | Venture capital |
| Founded | October 2014 |
| Founder | Bryan Johnson |
Area served | United States |
Key people | Bryan Johnson (General Partner), Jeff Klunzinger (General Partner) |
| Products | Venture capital investments in genomics, synthetic biology, computational therapeutics, advanced materials, diagnostics |
OS Fund is a United States-based venture capital firm that focuses on investing in early-phase companies within the science and technology sectors.
History
The inception of OS Fund dates back to October 2014, when Bryan Johnson established it, following the sale of Braintree to PayPal for $800 million the previous year. Johnson allocated $100 million from the proceeds of this transaction to initiate the fund. Both Johnson and Jeff Klunzinger act as general partners.
The creation of OS Fund was driven by Johnson's response to diminishing federal funding for research and development and the hesitancy of conventional venture capital to back startups focused on scientific innovation.
The fund's name derives from the abbreviation for operating system (OS) and concentrates on platform technologies in areas such as genomics, synthetic biology, computational therapeutics, advanced materials, and diagnostics.
In September 2015, OS Fund published its approach for evaluating investments in synthetic biology, aiming to stimulate increased funding in emerging scientific disciplines.
Investments
OS Fund primarily invests in early-stage companies that utilize computational methods, including artificial intelligence and machine learning, to create platform technologies across genomics, synthetic biology, computational therapeutics, advanced materials, and diagnostics.
Some key portfolio companies include:
- Ginkgo Bioworks, a biotechnology enterprise based in Boston specializing in genetically engineered bacteria for industrial uses; its market capitalization was approximately $0.5 billion as of June 2025.
- Atomwise, located in San Francisco, which develops an AI-based platform for drug discovery.
- twoXAR (currently known as Aria Pharmaceuticals), offering AI-driven drug discovery solutions.
- Catalog, a Boston-based firm innovating in DNA data storage capable of encoding 14 gigabytes of Wikipedia content along with a 240-page book into DNA strands.
- Matternet, a company that designs and manages drone logistics systems for on-demand delivery services; it collaborates with UPS and CVS Pharmacy to transport medical samples and prescriptions.